Liveome

Executive Summary

Liveome is a South Korean biotechnology company founded in 2020 that specializes in microbiome-based diagnostics and therapeutics for metabolic disorders such as obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD). The company utilizes advanced sequencing and bioinformatics to analyze gut microbiome composition and function, identifying microbial biomarkers associated with these conditions. By leveraging personalized health solutions, Liveome aims to address the growing global burden of metabolic diseases through precision medicine approaches. The company is currently in the preclinical stage and operates with a lean team of 10-50 employees in Seoul, South Korea. Despite being early-stage, Liveome addresses a rapidly expanding market where the gut microbiome is increasingly recognized as a key modulator of metabolic health. Its platform has the potential to differentiate through comprehensive biomarker discovery and proprietary therapeutic candidates. While specific funding and valuation details remain undisclosed, the company benefits from South Korea's strong biotech ecosystem and increasing interest in microbiome-based interventions. Key upcoming milestones include preclinical proof-of-concept data, strategic partnerships, and potential seed or Series A financing. If successful, Liveome could become a notable player in the metabolic microbiome space, though execution risks and validation challenges remain significant at this early stage.

Upcoming Catalysts (preview)

• Q4 2026Preclinical animal model data for lead candidate65% success
• Q2 2027Partnership with a major pharmaceutical or diagnostic company40% success
• Q3 2026Series A funding round announcement50% success